New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - corifollitropin alfa 0.2 mg/ml;   - solution for injection - 100 mcg/0.5ml - active: corifollitropin alfa 0.2 mg/ml   excipient: hydrochloric acid methionine polysorbate 20 sodium citrate sodium hydroxide sucrose water for injection - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - corifollitropin alfa 0.3 mg/ml;   - solution for injection - 150 mcg/0.5ml - active: corifollitropin alfa 0.3 mg/ml   excipient: hydrochloric acid methionine polysorbate 20 sodium citrate sodium hydroxide sucrose water for injection - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - finasteride 1mg - film coated tablet - 1 mg - active: finasteride 1mg excipient: docusate sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose purified talc sodium starch glycolate starch titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - desogestrel 150ug;  ; ethinylestradiol 20ug;   - tablet - active: desogestrel 150ug   ethinylestradiol 20ug   excipient: colloidal silicon dioxide dl-alpha tocopherol lactose monohydrate magnesium stearate potato starch povidone stearic acid lactose monohydrate magnesium stearate potato starch - oral contraception.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - follitropin beta 833 iu/ml;   - solution for injection - 833 iu/ml - active: follitropin beta 833 iu/ml   excipient: benzyl alcohol hydrochloric acid as 0.1n solution to adjust to ph 7.0 methionine polysorbate 20 sodium citrate dihydrate sodium hydroxide as 0.1n solution to adjust to ph 7.0 sucrose water for injection - in the female: - anovulatory infertility - controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programmes [e.g. in vitro fertilisation and related procedures].

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - betamethasone acetate 3 mg/ml; betamethasone sodium phosphate 3.9 mg/ml;   - solution for injection - active: betamethasone acetate 3 mg/ml betamethasone sodium phosphate 3.9 mg/ml   excipient: benzalkonium chloride dibasic sodium phosphate disodium edetate dihydrate monobasic sodium phosphate monohydrate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid; colecalciferol 140ug equivalent to 5600 iu;   - tablet - 70/140 - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid colecalciferol 140ug equivalent to 5600 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid; colecalciferol 70ug equivalent to 2800 iu;   - tablet - 70/70 - active: alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid colecalciferol 70ug equivalent to 2800 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 120mg; etoricoxib 120mg - film coated tablet - 120 mg - active: etoricoxib 120mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water active: etoricoxib 120mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.